Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.

导出 LinkOut

翻译打印收藏纠错

作者： Yasuyuki,Miyauchi ^[1] ; Hirohito,Naito ^[2] ; Hiroyuki,Tsunemori ^[2] ; Ryosuke,Tani ^[3] ; Yusuke,Hasui ^[3] ; Yuichi,Miyake ^[3] ; Tetsuo,Minamino ^[3] ; Ryo,Ishikawa ^[4] ; Yoshio,Kushida ^[4] ; Reiji,Haba ^[4] ; Mikio,Sugimoto ^[2]

作者单位： Department of Urology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho. Kita-gun, Kagawa, 761-0793, Japan. miyauchi@med.kagawa-u.ac.jp. ^[1] Department of Urology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho. Kita-gun, Kagawa, 761-0793, Japan. ^[2] Department of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan. ^[3] Department of Diagnostic pathology, Kagawa University Hospital, Kagawa, Japan. ^[4]

关键词 Immune checkpoint inhibitors Immune-related adverse events Immunotherapy Ipilimumab Myocarditis Nivolumab Renal cell carcinoma

主题词老年人(Aged);癌, 肾细胞(Carcinoma, Renal Cell);人类(Humans);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);心肌炎(Myocarditis)

DOI 10.1186/s13256-021-03097-6

PMID 34649593

发布时间 2021-10-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交